Moderna

Moderna Debt / Assets

Debt-to-Assets Ratio of Moderna (MRNA) as of Oct 25, 2026.

Debt / Assets

-

Last updated:

Debt-to-Assets Ratio of Moderna is 2026 - . Debt-to-Assets Ratio of Moderna was 2025 - . It decreases by % lower compared to the previous year.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Moderna Stock analysis

What does Moderna do? Moderna Inc is a biotechnology company from the USA that specializes in the development of therapies and vaccines based on mRNA technology. The company was founded in 2010 by a group of researchers led by Noubar Afeyan and is headquartered in Cambridge, Massachusetts. Moderna is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Moderna stock

On Eulerpool you can find the complete historical development of Debt-to-Assets Ratio Moderna since 2006 – with annual values, charts, and detailed analysis.

The Debt-to-Assets ratio measures what percentage of a company's assets are financed through debt. Higher ratios indicate greater financial risk.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Debt-to-Assets Ratio's Moderna with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Moderna

All Key Metrics — Moderna